News | Heart Failure | February 22, 2017

New RightSTEPS Educational Initiative to Drive Change in Clinician Prescribing Behavior for Chronic Heart Failure

Blended-learning initiative provides comprehensive education to empower clinicians to take the RightSTEPS to treat the right patients with the right drugs at the right dose at the right time

ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure

February 22, 2017 — The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have joined forces to develop RightSTEPS: Optimizing Medical Therapy for Chronic Heart Failure. This long-term education initiative aims to help clinicians follow prescribing guidelines to reduce hospitalizations and readmissions and to improve patient outcomes to address the 75 percent of chronic heart failure (HF) patients who do not receive optimal doses of guideline-recommended drugs.

Launching in 2017, with additional education to be added regularly throughout the year, the program is overseen by leading experts in HF treatment, including Akshay S. Desai, M.D., MPH, FACC, director, heart failure disease management, Cardiovascular Division, Brigham and Women’s Hospital and associate professor of ,edicine, Harvard Medical School. The curriculum includes American College of Cardiology/American Heart Association guideline-driven medical therapy, and it enables clinicians to:

  • Learn via a dedicated online Cardiology Learning Center on myCME offering self-paced, personalized educational activities that are eligible for up to 16 continuing medical education (CME)/continuing nursing education (CNE) complimentary credits, including individualized treatments for various gender and racial/ethnic populations;
  • Practice during face-to-face live meetings at regional healthcare systems, with parallel sessions for patients and caregivers at Veterans Affairs hospitals; and
  • Perform and receive customized online coaching that qualifies as a Centers for Medicare & Medicaid Services (CMS) Quality Payment Program Improvement Activity under the new Merit-based Incentive Payment System (MIPS).

“Improving heart health is at the core of the ACC’s mission,” said Desai, ACC RightSTEPS chair and course director. “With RightSTEPS, medical professionals treating heart failure patients have easier access to the tools they need to make informed, guideline-driven decisions and provide their patients with the highest quality care.”

“Successful treatment of chronic HF depends on both medical knowledge and ongoing dialogue,” said Priya Wanchoo, M.D., medical director of myCME. “We’re pleased the education we develop with the ACC for RightSTEPS will have a dedicated home on myCME. We believe it will provide clinicians a support center for their efforts in providing optimal patient care.”

Supported by an independent educational grant from Novartis Pharmaceuticals Corporation, the curriculum is designed for the range of clinicians who provide care for patients with chronic HF, including cardiologists, internists, primary care physicians, nurses, nurse practitioners and physician assistants. To further close the circle and improve performance, it includes education geared for patients with chronic HF and their caregivers.

For more information: www.mycme.com/rightsteps

Related Content

Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

News | Heart Failure | March 12, 2019
V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief...
Overlay Init